These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36831610)

  • 21. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined BRAF
    Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T
    J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
    Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
    J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

  • 25. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.
    Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ
    Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response and resistance to BRAF
    Capogiri M; De Micheli AJ; Lassaletta A; Muñoz DP; Coppé JP; Mueller S; Guerreiro Stucklin AS
    Front Oncol; 2022; 12():1074726. PubMed ID: 36698391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular-targeted therapy for childhood low-grade glial and glioneuronal tumors.
    Siegel BI; Duke ES; Kilburn LB; Packer RJ
    Childs Nerv Syst; 2024 Oct; 40(10):3251-3262. PubMed ID: 38877124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH-mutant gliomas with additional class-defining molecular events.
    Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S
    Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapies for pediatric low grade glioma.
    Demaliaj D; Gardner SL
    Curr Opin Neurol; 2024 Dec; 37(6):702-707. PubMed ID: 39324939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
    Boufraqech M; Patel D; Nilubol N; Powers A; King T; Shell J; Lack J; Zhang L; Gara SK; Gunda V; Klubo-Gwiezdzinska J; Kumar S; Fagin J; Knauf J; Parangi S; Venzon D; Quezado M; Kebebew E
    Thyroid; 2019 Jan; 29(1):79-92. PubMed ID: 30398411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Role of BRAF Mutation in Low-Grade Gliomas: Meta-analysis.
    Kai Z; Dingyang L; Zhuanyi Y
    World Neurosurg; 2021 Mar; 147():42-46. PubMed ID: 33316486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of
    Wagner MW; Hainc N; Khalvati F; Namdar K; Figueiredo L; Sheng M; Laughlin S; Shroff MM; Bouffet E; Tabori U; Hawkins C; Yeom KW; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2021 Apr; 42(4):759-765. PubMed ID: 33574103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabrafenib Plus Trametinib: An Impressive Response in an Adult Patient With BRAF V600E-Mutated and Isocitrate Dehydrogenase (IDH) Wild-Type Glioma.
    Costa IN; Reis J; Pinheiro J; Silva R; Fernandes C
    Cureus; 2022 Aug; 14(8):e28156. PubMed ID: 36158392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
    Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
    Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.
    Myung JK; Cho H; Park CK; Kim SK; Lee SH; Park SH
    Transl Oncol; 2012 Dec; 5(6):430-6. PubMed ID: 23323158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pediatric Glioma].
    Terashima K; Ogiwara H
    No Shinkei Geka; 2021 May; 49(3):640-646. PubMed ID: 34092570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.